Skip to main content
SpringerLink
Log in

Schwerpunkt Dünndarmtumoren

Diagnostik und Therapie von GIST aus internistischer Sicht

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Etwa ein Drittel aller gastrointestinalen Stromatumoren (GIST) sind im Dünndarm lokalisiert, am häufigsten finden sie sich im Magen. Die Diagnose, die Einschätzung der Dignität und die Risikostratifizierung der GIST kann Behandler vor große Herausforderungen stellen. Lesen Sie nachfolgend, was dabei zu beachten ist und wie sich GIST systemisch behandeln lassen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Nilsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005;103(4):821–9

    Article  Google Scholar 

  2. Scarpa M et al. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008;98(5):384–92

    Article  Google Scholar 

  3. Chak A et al. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointestinal endoscopy. 1997;45(6):468–73

    Article  CAS  Google Scholar 

  4. Casali PG et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv68–iv78

    Article  CAS  Google Scholar 

  5. Kiśluk J et al. Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours - an analysis of 70 cases from 2004 to 2010. Prz Gastroenterol. 2016;11(2):115–22

    PubMed  Google Scholar 

  6. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 2010;3(5):461–71

    PubMed  PubMed Central  Google Scholar 

  7. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9

    Article  Google Scholar 

  8. Vernuccio F et al. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. Anticancer Res. 2016;36(6):2639–48

    CAS  PubMed  Google Scholar 

  9. Debiec-Rychter M et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093–103

    Article  CAS  Google Scholar 

  10. Joensuu H et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72

    Article  CAS  Google Scholar 

  11. Iwatsuki M et al. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2019;3(1):43–9

    Article  Google Scholar 

  12. Demetri GD et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38

    Article  CAS  Google Scholar 

  13. George S et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959–68

    Article  CAS  Google Scholar 

  14. Demetri GD et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302

    Article  CAS  Google Scholar 

  15. Kang YK et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–82

    Article  CAS  Google Scholar 

  16. Choi H et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753–9

    Article  Google Scholar 

  17. Farag S et al. Early Evaluation of Response Using (18)F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. J Nucl Med. 2018 Feb;59(2):194–196

    Article  CAS  Google Scholar 

  18. Le Cesne A et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27(24):3969–74

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum München, Ludwig-Maximilians-Universität, München, Deutschland

    Daniel Rössler, Enrico de Toni, Jörg Schirra &  Julia Mayerle (Direktorin)

  2. Medizinische Klinik und Poliklinik II Klinikum der LMU München-Grosshadern, Marchioninistr. 15, 81377, München, Deutschland

    Daniel Rössler &  Julia Mayerle (Direktorin)

Authors
  1. Daniel Rössler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrico de Toni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg Schirra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julia Mayerle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Daniel Rössler or Julia Mayerle.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rössler, D., de Toni, E., Schirra, J. et al. Diagnostik und Therapie von GIST aus internistischer Sicht. Info Onkol. 22, 25–28 (2019). https://doi.org/10.1007/s15004-019-6514-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6514-0

Search

Navigation